|
|
Correlation Analysis Between Imaging Features Clinicopathological Characteristics and Molecular Subtypes of Non-Mass Ductal Carcinoma In Situ (DCIS) |
LIU Fang, ZHOU Menghong, WANG Haijuan, et al |
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Hunan Changsha 410007, China |
|
|
Abstract Objective: To investigate the relationship between the imaging features and the clinicopathological characteristics of non-mass ductal carcinoma in situ (DCIS) and to analyze their correlation with molecular subtypes. Methods: This study selected 100 patients with non-mass DCIS who underwent surgical treatment at our hospital from June 2020 to June 2021.The patients were classified into four types (Type I:31 cases,Type Ⅱ:15 cases,Type Ⅲ:43 cases,and Type Ⅳ:11 cases) based on ultrasound findings.Immunohistochemistry was used to evaluate the positive expression of estrogen receptor (ER),progesterone receptor (PR),human epidermal growth factor receptor 2 (HER2),and Ki-67.Patients were categorized into Luminal A and Luminal B molecular subtypes according to the St.Gallen standard. Results: Type I exhibited thickened and tortuous ducts with low echogenicity within the lumen.Type Ⅱ displayed patchy hypoechoic areas with indistinct boundaries in the breast.Type Ⅱ showed lamellar hypoechoic areas with unevenly distributed punctate strong echoes in the breast.Type Ⅳ presented disordered glandular structures with distorted architecture.There were no statistically significant differences in age,tumor diameter,menstrual status,lesion location,and clinical symptoms among patients with Type I,Type Ⅱ,Type Ⅲ,and Type Ⅳ non-mass DCIS (P>0.05).However,as the ultrasound classification level increased,nuclear grade also increased (P<0.05).There were no significant differences in the positive expression of ER,PR,Ki-67 levels among Type I,Type Ⅱ,Type Ⅲ and Type Ⅳ non-mass DCIS patients (P>0.05).But,there was a significant difference in HER2 positive expression between Type I and Type Ⅱ,with Types Ⅲ and Ⅳ showing a higher HER2 positive expression (P<0.05).There was no significant difference in HER2 positive expression between type I and type II patients (P>0.05). Compared to type I, type III and type IV showed higher HER2 positive expression (P<0.05). Type III had higher HER2 positive expression compared to type II, but the difference with type IV was not statistically significant (P>0.05). The distribution of Luminal A and Luminal B subtypes increased in type III compared to type I (P<0.05), and the distribution of Luminal B subtype increased in type IV compared to type I (P<0.05), while the difference in Luminal A subtype was not statistically significant (P>0.05). Conclusion: Patients with non-mass DCIS mainly exhibited calcification on ultrasound.Patients with structural disorders had higher nuclear grades and more HER2 positive expression.These factors were correlated with a decrease in Luminal A subtype and an increase in Luminal B subtype.
|
|
|
|
|
[1] 雷少元,郑荣寿,张思维,等.乳腺癌发病率和死亡率的全球模式:一项基于人群的2000年至2020年肿瘤登记数据分析研究[J].癌症,2022,41(7):324-335. [2] Knowlton CA,Jimenez RB,Moran MS.DCIS:Risk assessment in the molecular era[J].Semin Radiat Oncol.2022,32(3):189-197. [3] 邢博缘,张秉宜,刘捷,等.常规超声结合弹性成像对特发性肉芽肿性乳腺炎和导管内原位癌的鉴别诊断价值[J].中国医药导报,2022,19(7):19-22. [4] 杨敏.非肿块型乳腺癌的超声表现与病理的相关性研究[D].江苏:苏州大学,2019. [5] 胡夕春,王碧芸,邵志敏,等.2011年《St.Gallen早期乳腺癌初始治疗国际专家共识》与中国抗癌协会乳腺癌专业委员会指南之比较[J].中华乳腺病杂志,2021,5(4):404-407. [6] Trapani D,Curigliano G.Accelerating progress in early triple-negative breast cancer:a viewpoint on antibody-drug conjugates,back from St Gallen breast cancer conference 2021[J].Breast,2022,62(1):54-57. [7] 王刚,张盼盼,马兆生,等.ABUS联合常规超声在非肿块型乳腺癌中的诊断价值[J].浙江临床医学,2022,24(10):1516-1518. [8] 苏晓慧,李超,林青,等.乳腺断层摄影和超声对不同病理级别非钙化型导管原位癌的诊断效能[J].中国医学影像学杂志,2022,30(11):1130-1135. [9] 段克举,杨亚芳,刘真真.钙化型及非钙化型乳腺导管原位癌的病理分级及免疫组织化学特征[J].临床放射学杂志,2021,40(1):42-47. [10] 商瑞苗,杨道玲,孔敏刚,等.常规超声和弹性成像技术在非肿块型乳腺病变中的诊断价值比较[J].中国现代医生,2021,59(32):130-132,136. [11] 陶振洲,秦薛斌,曹广,等.老年女性乳腺癌患者的临床特点及预后分析[J].中国医药,2022,17(3):330-333. |
|
|
|